TGFB1 and neoplasm: These results suggest that blocking TGF-β activated in the close vicinity of Tregs, thanks to anti-CTLA-4 antibody, or in the close vicinity of other immune cells or tumor cells, thanks to the anti-PD-L1 antibody, is not only sufficient for anti-tumor activity, but also more efficient than systemic blockade of TGF-β.